1157. Immune Persistence and Booster Response of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) 5 Years After Primary Vaccination of Adults ≥59 Years of Age

BACKGROUND: MenACYW-TT (MenQuadfi®, Sanofi) is a quadrivalent (serogroups A, C, W, and Y) meningococcal tetanus toxoid conjugate vaccine. It is approved for use in persons aged ≥2 years in the US and persons aged ≥1 year in Europe and certain other countries; trials in infants as young as 6 weeks ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Robertson, Corwin A, Galarza, Katherine, Jacqmein, Jeffry, Selmani, Alexandre, Oster, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676863/
http://dx.doi.org/10.1093/ofid/ofad500.997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676863/
http://dx.doi.org/10.1093/ofid/ofad500.997

Ejemplares similares